Mineralys Therapeutics, Inc. Common Stock
Symbol: MLYS (NASDAQ)
0.00
▼ (-100.00%) -43.370
Company Description:
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $43.37
- Yesterday High: $44.6
- Yesterday Low: $43.31
- Yesterday Volume: 681.39K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Mineralys Therapeutics, Inc. Common Stock
- Website: https://mineralystx.com
- Listed Date: 2023-02-10
- Location: RADNOR, PA
- Market Status: Active
- CIK Number: 0001933414
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $3.43B
- Round Lot: 100
- Outstanding Shares: 77.57M
- Asset Type: CS
RECENT FILINGS FOR MLYS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-15 | 4 | View |
| 2025-10-15 | 4 | View |
| 2025-10-15 | 4 | View |
| 2025-10-15 | 144 | View |
| 2025-10-14 | 144 | View |
| 2025-10-14 | 144 | View |
| 2025-09-16 | 4 | View |
| 2025-09-15 | 144 | View |
| 2025-09-08 | 4 | View |
| 2025-09-08 | SCHEDULE 13D/A | View |
| 2025-09-08 | SCHEDULE 13D/A | View |
| 2025-09-08 | 4 | View |
| 2025-09-03 | 8-K | View |
| 2025-09-03 | 424B5 | View |
| 2025-09-02 | S-3MEF | View |
| 2025-09-02 | 8-K | View |
| 2025-09-02 | 424B5 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
Latest News on MLYS